Skip to main content

Table 4 Health benefit results of cost-effectiveness modelling with different transition probability matrices

From: Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine

 

Source of the transition probability matrix

Only the clinical trial

Expert opinion + clinical trial

Vague prior + clinical trial

QALY cariprazine

0.7562

0.7540

0.7512

QALY risperidone

0.7302

0.7287

0.7269

QALY difference

0.0260

0.0253

0.0243